This is an outdated version published on 2019-10-31. Read the most recent version.
Refractoriness to treatment of Kawasaki disease with intravenous immunoglobulin:a retrospective analysis a retrospective analysis
DOI:
https://doi.org/10.51723/ccs.v30i01.453Keywords:
Doença de Kawasaki; tratamento farmacológico; imunoglobulinaAbstract
The objective of the study is to analyze the factors that influenced refractoriness in the treatment of Kawasaki disease with intravenous immunoglobulin in the pediatric rheumatology service of the Hospital of the Child of Brasília José Alencar. The research is retrospective (case-control) and comparative (refractory x responsive). Epidemiological, clinical and laboratorial data were evaluated, being the only variable with statistical relevance (p = 0,006) the highest level of platelets in refractory, suggesting a higher risk of complications such as thrombus formation. The prediction of risk to refractoriness remains a challenge, requiring a targeted approach to the Brazilian population.
Downloads
Download data is not yet available.
References
1. Mccrindle, BW et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association, Circulation. 2017 Apr 25;135(17):e927-e999. doi: 10.1161/CIR.0000000000000484. Epub 2017 Mar 29.
2. Castro PA, Urbano LMF, Costa IMC. Doença de Kawasaki. An Bras Dermatol. 2009;84(4):317-31.
3. Burns, J. C.; Glode, M. P. Kawasaki syndrome. Lancet. 2004 Aug 7-13;364(9433):533-44.
4. Sano T et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007 Feb;166(2):131-7. Epub 2006 Aug 1.
5. Egami K et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006 Aug;149(2):237-40.
6. Takeuchi M et al. Novel Risk Assessment Tool for Immunoglobulin-Resistance in Kawasaki Disease. Pediatr Infect Dis J. 2017 Sep;36(9):821-826. doi: 10.1097/INF.0000000000001621.
7. Khor CC et al. Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. J Med Genet. 2011 Jul;48(7):467-72. doi: 10.1136/jmg.2010.086611. Epub 2011 May 13.
8. Shrestha S et al. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. J Allergy Clin Immunol. 2011 Sep;128(3):677-80. doi: 10.1016/j.jaci.2011.04.027. Epub 2011 May 20.
9. Sánchez-Manubens J et al. Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population. Rheumatol Int. 2016 Jul;36(7):905-10. doi: 10.1007/s00296-016-3499-y. Epub 2016 May 23.
10. Qian W et al. A comparison of efficacy of six prediction models for intravenous immunoglobulin resistance in Kawasaki disease. Ital J Pediatr. 2018 Mar 9;44(1):33. doi: 10.1186/s13052-018-0475-z.
11. Sleeper LA et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011 May;158(5):831-835.e3. doi: 10.1016/j.jpeds.2010.10.031. Epub 2010 Dec 18.
12. Seki M, Kobayashi T, Kobayashi T, Morikawa A; et al. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with Kawasaki disease. Pediatr Infect Dis J. 2011 Feb;30(2):145-7. doi: 10.1097/INF.0b013e3181f386db.
13. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006 Jun 6;113(22):2606-12. Epub 2006 May 30.
14. Manlhiot C, Millar K, Golding F, McCrindle B. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pedriatr Cardiol. 2010; 31: 242-249.
15. Managing scarlat fever. BMJ. 2018 Aug 30;362:k3005. doi: 10.1136/bmj.k3005.
16. Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease. Singapore Med J. 2006 Sep;47(9):780-4.
17. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease: US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17:1144–1148.
18. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and re- treatment in Kawasaki disease. Pediatr Cardiol. 2003;24:145–148. doi: 10.1007/s00246-002-0216-2.
19. Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J. 2008;27:155–160.
2. Castro PA, Urbano LMF, Costa IMC. Doença de Kawasaki. An Bras Dermatol. 2009;84(4):317-31.
3. Burns, J. C.; Glode, M. P. Kawasaki syndrome. Lancet. 2004 Aug 7-13;364(9433):533-44.
4. Sano T et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007 Feb;166(2):131-7. Epub 2006 Aug 1.
5. Egami K et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006 Aug;149(2):237-40.
6. Takeuchi M et al. Novel Risk Assessment Tool for Immunoglobulin-Resistance in Kawasaki Disease. Pediatr Infect Dis J. 2017 Sep;36(9):821-826. doi: 10.1097/INF.0000000000001621.
7. Khor CC et al. Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. J Med Genet. 2011 Jul;48(7):467-72. doi: 10.1136/jmg.2010.086611. Epub 2011 May 13.
8. Shrestha S et al. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. J Allergy Clin Immunol. 2011 Sep;128(3):677-80. doi: 10.1016/j.jaci.2011.04.027. Epub 2011 May 20.
9. Sánchez-Manubens J et al. Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population. Rheumatol Int. 2016 Jul;36(7):905-10. doi: 10.1007/s00296-016-3499-y. Epub 2016 May 23.
10. Qian W et al. A comparison of efficacy of six prediction models for intravenous immunoglobulin resistance in Kawasaki disease. Ital J Pediatr. 2018 Mar 9;44(1):33. doi: 10.1186/s13052-018-0475-z.
11. Sleeper LA et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011 May;158(5):831-835.e3. doi: 10.1016/j.jpeds.2010.10.031. Epub 2010 Dec 18.
12. Seki M, Kobayashi T, Kobayashi T, Morikawa A; et al. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with Kawasaki disease. Pediatr Infect Dis J. 2011 Feb;30(2):145-7. doi: 10.1097/INF.0b013e3181f386db.
13. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006 Jun 6;113(22):2606-12. Epub 2006 May 30.
14. Manlhiot C, Millar K, Golding F, McCrindle B. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pedriatr Cardiol. 2010; 31: 242-249.
15. Managing scarlat fever. BMJ. 2018 Aug 30;362:k3005. doi: 10.1136/bmj.k3005.
16. Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease. Singapore Med J. 2006 Sep;47(9):780-4.
17. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease: US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17:1144–1148.
18. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and re- treatment in Kawasaki disease. Pediatr Cardiol. 2003;24:145–148. doi: 10.1007/s00246-002-0216-2.
19. Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J. 2008;27:155–160.
Downloads
Published
2019-10-31
Versions
- 2020-07-19 (2)
- 2019-10-31 (1)
Issue
Section
Clínica Assistencial
License
Declaro para os devidos fins que o artigo que estou submetendo representa um trabalho original e nunca foi publicado total ou parcialmente, e que se alguma de suas partes foi publicada possuímos autorização expressa para a publicação no periódico Comunicação em Ciências da Saúde (CCS). Esse artigo não foi enviado a outro periódico e não o será enquanto estiver sendo considerada sua publicação; caso venha a ser aceito não será publicado em outro periódico; e não contém material difamatório ou ilegal sob nenhuma forma, não viola a intimidade de terceiros, nem infringe direitos protegidos.
Eu e demais autores desse trabalho certificamos por meio desta declaração que:
- Concordamos com as normas editoriais e com o processo de revisão da CCS;
- Aceitamos a responsabilidade pela conduta desse estudo e pela análise e interpretação dos dados;
- Cooperaremos, sempre que solicitado, na obtenção e fornecimento de dados sobre os quais o manuscrito está baseado, para exame dos avaliadores;
- Não estão sendo omitidos quaisquer ligações ou acordos de financiamento entre os autores e companhias ou pessoas que possam ter interesse no material abordado no artigo;
- Não estão sendo excluídos ou omitidos deste artigo autores ou instituições participantes;
- Possuímos permissão para uso de figuras e tabelas publicadas em outras fontes;
- Possuímos permissão das pessoas e instituições citadas nos agradecimentos;
- O autor correspondente autoriza a publicação do endereço informado e e-mail do(s) autor(es) junto com o artigo;
- Assumimos a responsabilidade pela entrega de documentos verídicos;
- Autorizamos a publicação do referido artigo no periódico Comunicação em Ciências da Saúde, segundo critérios próprios e em número e volume a serem definidos pelo editor do periódico;
- Nos comprometemos a atender os prazos estipulados pelos editores do periódico Comunicação em Ciências da saúde;
- Estamos cientes de que a não manifestação no prazo de dois dias da revisão da diagramação, recebida por e-mail, será considerado aprovado para publicação.
How to Cite
1.
Refractoriness to treatment of Kawasaki disease with intravenous immunoglobulin:a retrospective analysis a retrospective analysis. Com. Ciências Saúde [Internet]. 2019 Oct. 31 [cited 2024 Nov. 20];30(01). Available from: https://revistaccs.espdf.fepecs.edu.br/index.php/comunicacaoemcienciasdasaude/article/view/453
